Abbott MediaRoom - Press Releases -->
Mother and son jogging Mother and son jogging Mother and son jogging Mother and son jogging
Advanced Search
  • Feb 17, 2022
    Abbott Voluntarily Recalls Powder Formulas Manufactured at One Plant
    Recall is isolated to powder formulas, including Similac®, Alimentum ® and EleCare®, manufactured at the Sturgis, Mich., plant
    Recall does not include any metabolic deficiency nutrition formulas
    No Abbott liquid formulas or other Abbott nutrition powders and brands are impacted
    Parents or customers with impacted product should visit similacrecall.com or call +1-800-986-8540
  • Feb 7, 2022
    Abbott Announces World's First Implant of Dual-Chamber Leadless Pacemaker in Pivotal Trial
    - Abbott's investigational Aveir™ DR dual-chamber pacemaker is designed to provide synchronous, beat-by-beat pacing of the right atrium and right ventricle of the heart
    - Proprietary implant-to-implant (i2i™) device technology is used for communication between two implanted leadless pacemakers to regulate the heart rate
    - Aveir DR is also specifically designed to be retrieved if therapy needs evolve
  • Feb 3, 2022
    UnitedHealthcare Extends Coverage to Abbott’s Unique Neurostimulation Therapy for Nerve Pain
    - Abbott’s Proclaim™ dorsal root ganglion (DRG) neurostimulation system is the only FDA-approved DRG technology for the treatment of CRPS I and causalgia of the lower extremitiesi
    - UnitedHealthcare is the largest private health insurance company in the U.S, providing coverage for more than 44 million healthcare membersii
  • Jan 26, 2022
    Abbott Reports Strong Fourth-Quarter 2021 Results; Issues 2022 Forecast
    - Fourth-quarter sales growth of 7.2 percent; organic sales growth of 7.7 percent
    - Global COVID-19 testing-related sales of $2.3 billion in the fourth quarter
    - Excluding COVID-19 testing-related sales, fourth-quarter sales growth of 9.6 percent and organic sales growth of 10.3 percent
    - Full-year 2021 sales growth of 24.5 percent; organic sales growth of 22.9 percent
    - Full-year 2021 GAAP diluted EPS from continuing operations growth of 58.2 percent; adjusted diluted EPS growth of 42.7 percent
    - R&D pipeline continues to deliver a steady cadence of new products, including several in large, fast-growing markets
  • Jan 12, 2022
    Abbott Receives U.S. FDA Clearance for New Cardiac Mapping System to Improve How Doctors Treat Abnormal Heart Rhythms
    - EnSite™ X EP System with EnSite Omnipolar Technology (OT) provides a 360-degree view of the heart, regardless of catheter orientation, for cardiac mapping without compromise
Show 5102550100 per page
true
accessibility

You are about to exit for another Abbott country or region specific website

Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions.


The website you have requested also may not be optimized for your specific screen size.

Do you wish to continue and exit this website?

yesno
accessibility

You are about to exit the Abbott family of websites for a 3rd party website

Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott.


The website that you have requested also may not be optimized for your screen size.

Do you wish to continue and exit this website?

yesno
accessibility

Asset Warning

yesno